Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|September 28, 2023
Harnessing Immune Response in Acute Myeloid LeukemiaCarola Riva, Chiara Vernarecci, Paola Minetto, et al.
Leukemia & Lymphoma|September 5, 2019
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomasLorenzo Manconi, Elisa Coviello, Filippo Canale, et al.
Cancers|December 1, 2020
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate LymphocytesSilvia Pesce, Sara Trabanelli, Clara Di Vito, et al.
American Journal of Hematology|April 17, 2016
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Frontiers in Immunology|March 3, 2023
Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoireRaffaella Meazza, Loredana Ruggeri, Fabio Guolo, et al.
Annals of Hematology|May 21, 2013
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question"Marino Clavio, Fabio Cruciani, Paola Minetto, et al.
Leukemia Research|September 27, 2019
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemiaRiccardo Marcolin, Fabio Guolo, Paola Minetto, et al.
Leukemia & Lymphoma|March 19, 2020
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Hematological Oncology|December 5, 2024
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual DiseaseCarola Riva, Paola Minetto, Maria Chies, et al.
Cancers|December 30, 2020
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic BurdenPaola Minetto, Anna Candoni, Fabio Guolo, et al.
Pageof 5